Engineering heparin-azithromycin microparticulate nasal gels for the dual prophylaxis and therapy of COVID-19 and bacterial respiratory infections

Tools

Anaya Meza, Bryan Javier and Osouli Bostanabad, Karim and Tirado, Diego F and Gonzalez-Burgos, Elena and Lalatsa, Katerina and Serrano Lopez, Dolores Remedios (2025) Engineering heparin-azithromycin microparticulate nasal gels for the dual prophylaxis and therapy of COVID-19 and bacterial respiratory infections. In: 15th PBP World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 2026-03-23 - 2026-03-26, Prague Congress Centre. (In Press)

[thumbnail of Anaya-Meza-etal-PBPWM-2026-Engineering-heparin-azithromycin-microparticulate-nasal-gels-for-the-dual] Text. Filename: Anaya-Meza-etal-PBPWM-2026-Engineering-heparin-azithromycin-microparticulate-nasal-gels-for-the-dual.pdf
Accepted Author Manuscript
Restricted to Repository staff only until 1 January 2099.
Download (469kB) | Request a copy

Abstract

The SARS-CoV-2 pandemic highlighted the need for effective prophylactic and local treatment strategies against respiratory viruses. The nasal cavity is a critical site for pathogen entry and colonization, and is therefore a critical target for targeted interventions. SARS-CoV-2, as a plethora of other virus, primarily spreads via respiratory droplets infecting nasal epithelial cells. Concurrently, bacteria such as Streptococcus pneumoniae and Pseudomonas aeruginosa, frequently colonize the nasal cavity, causing co-infections and serving as reservoirs for further respiratory tract involvement. This study presents a nasal gel that combines heparin and azithromycin (AZM) microparticles to combat both viral and bacterial infections in the nasal cavity. The formulation exhibits a favorable safety profile with minimal haemolytic toxicity (HC50 > 82 × 10⁷ μg/mL), potent activity against P. aeruginosa and S. pneumoniae at low concentrations (MIC of 15.6 µg/mL and 7.8 µg/mL, respectively), and effective antiviral properties (IC50 of 0.062 µg/mL for Pseudovirus inhibition). These multifaceted properties position the formulation as a promising candidate for a convenient, dual-action therapy in respiratory infection management, offering potentially both treatment and prophylaxis.

ORCID iDs

Anaya Meza, Bryan Javier, Osouli Bostanabad, Karim ORCID logoORCID: https://orcid.org/0000-0003-4375-4948, Tirado, Diego F, Gonzalez-Burgos, Elena, Lalatsa, Katerina ORCID logoORCID: https://orcid.org/0000-0003-4791-7468 and Serrano Lopez, Dolores Remedios;
CORE (COnnecting REpositories)